IDEXX Laboratories Surges 10% on Strong Q4 Earnings and Optimistic 2025 Outlook

IDEXX Laboratories (NASDAQ:IDXX) delivered stronger-than-expected fourth-quarter results, propelling its stock up 10% intra-day today. The pet healthcare company outperformed Wall Street estimates on both earnings and revenue, fueled by consistent growth in its Companion Animal Group (CAG) segment and recurring diagnostic services.

For the quarter, IDEXX reported adjusted earnings per share of $2.62, well above the analyst consensus of $2.39. Revenue climbed 6% year-over-year to $954.28 million, exceeding expectations of $933.38 million. The company’s CAG segment led the way, posting a 6% revenue increase, while recurring revenue from CAG Diagnostics rose 7% organically, demonstrating strong demand for its veterinary testing and diagnostic solutions.

Looking ahead, IDEXX issued an optimistic forecast for 2025, projecting revenue between $4.05 billion and $4.17 billion, reflecting 4-7% reported growth and 6-9% organic growth. Adjusted earnings per share are expected to range from $11.74 to $12.24, reinforcing confidence in continued expansion. The company also anticipates steady volume growth and a 4-4.5% pricing benefit throughout the year, supporting sustained momentum in its core business.